Profile
Gregory S.
Naeve worked as Director at Circle Pharma, Inc., Principal at Amgen, Inc., Principal at Neurocrine Biosciences, Inc., Head-ImmunoOncology & Cell Therapy at Pfizer Inc. from 2012 to 2017, Chief Business Officer at Bellicum Pharmaceuticals, Inc. from 2017 to 2019, and President & Chief Scientific Officer at Parallax Biosystems, Inc. from 2002 to 2007.
He holds a doctorate from the University of Southern California and an undergraduate degree from Colorado State University.
Former positions of Gregory S. Naeve
| Companies | Position | End |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2019-09-30 |
| PFIZER, INC. | Corporate Officer/Principal | 2017-07-31 |
| Parallax Biosystems, Inc. | President | 2006-12-31 |
Circle Pharma, Inc.
 Circle Pharma, Inc. BiotechnologyHealth Technology Circle Pharma, Inc. provides biotechnology services. The company was founded by Matthew P. Jacobson and Scott Lokey in June 2014 and is headquartered in San Francisco, CA. | Director/Board Member | - |
| AMGEN INC. | Corporate Officer/Principal | - |
Training of Gregory S. Naeve
| University of Southern California | Doctorate Degree |
| Colorado State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| NEUROCRINE BIOSCIENCES, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Private companies | 4 |
|---|---|
The Column Group LLC
 The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Finance |
Circle Pharma, Inc.
Circle Pharma, Inc. BiotechnologyHealth Technology Circle Pharma, Inc. provides biotechnology services. The company was founded by Matthew P. Jacobson and Scott Lokey in June 2014 and is headquartered in San Francisco, CA. | Health Technology |
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
| Parallax Biosystems, Inc. |
- Stock Market
- Insiders
- Gregory S. Naeve
